Agalsidase beta Completed Phase 1 Trials for Fabry's Disease Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00357786An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
NCT02930655A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease